November 2023

Alpaca Antibody Discovery and Characterization with Polyclonal Sequencing, SPR and HDX-MS

2023-11-14T11:28:27-05:00November 13th, 2023|Case Studies|

Authors:  Teresa Nunez, Amber Couzens, Jin Duan, Chelsea Reitzel, Rosalin Dubois,  Lin Wu, Qixin Liu, Thierry Le Bihan, Marko Jović, Dominic Narang, Bin Ma  Published: Nov 13, 2023 Abstract In this study, the challenge of accessing functional antibodies from the circulating antibody repertoire was addressed using Rapid Novor's [...]

October 2023

July 2023

April 2023

December 2022

Technologies for Antibody Discovery and Generation

2023-06-21T11:03:32-04:00December 23rd, 2022|Articles|

The great debate on the use of in vivo versus in vitro sources and strategies for antibody discovery and generation continues to thrive among antibody research groups. On one side of the debate is the argument for non-animal-derived antibodies due to the technical advancements of current in vitro technologies, and the moral obligation to reduce animal usage. On the other side of the debate is the counterargument for animal-derived antibodies due to their better performance in affinity, specificity, and reduced immunogenicity risk.

October 2022

Selecting Specific Monoclonal Antibodies by SPR – Alpaca Antibody Showdown

2023-05-15T12:44:34-04:00October 30th, 2022|Webinars|

In this SPR webinar, you will learn: How SPR works and its unique advantages for kinetic analysis of antibody-antigen interactions Applications of SPR in antibody discovery Functionality of SPR in antibody characterization Abstract Due to their ability to bind biomolecules specifically and tightly, antibodies are highly [...]

July 2022

Adeno-Associated Virus Vectors for Gene Therapy Delivery

2023-06-22T10:41:47-04:00July 14th, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: July 11, 2022 Contents What is Gene Therapy? What are Adeno-Associated Viruses? Engineering of AAVs for Gene Therapy Engineering AAVs for Improved Transduction Engineering AAVs for Improved Immunogenicity De Novo Protein Sequencing Applications in AAV Characterization and Development What is Gene [...]

June 2022

Chimeric Antigen Receptors and T cells – CAR-T

2023-06-22T10:39:28-04:00June 21st, 2022|Articles|

Written by: Vanessa Yoon Calvelo, PhD Published: June 13, 2022 Contents What is CAR-T Cell Therapy? CAR Structure and Function CAR-T Cell Development Engineering Strategies for CAR-T Cells De Novo Protein Sequencing Applications in CAR-T Cell Development What is CAR-T Cell Therapy? The infusion of T cells [...]

What is Polyclonal Antibody Sequencing?

2023-06-21T11:00:39-04:00June 1st, 2022|Articles|

The most straightforward solution would be to determine sequences of the dominating antibody forms in a polyclonal mixture to enable recombinant antibody generation and ensure reproducibility. This was recently made possible by the development of polyclonal antibody sequencing technology, which will be reviewed in this article.

April 2022

Broadly Neutralizing Antibody Cocktails Targeting Nipah Virus and Hendra Virus Fusion Glycoproteins

2023-06-21T10:18:26-04:00April 29th, 2022|Case Studies|

Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.

March 2022

First Immunoassay for Measuring Isoaspartate in Human Serum Albumin

2023-06-21T10:52:50-04:00March 25th, 2022|Case Studies|

The ongoing pandemic has reinforced the need for in vitro diagnostics to globally surveille emerging pathogens and provide better medical care. In particular, immunoassays are favoured due to their affordability, ease, and speed. Nevertheless, the combination of rapidly evolving pathogens, and more complex diseases resulting from increasing life expectancy worldwide require more sensitive and specific immunoassays in the nick of time. To increase sensitivity, immunoassay development can benefit from exploiting industry-leading technologies such as de novo protein sequencing.

February 2022

Camelid Antibodies and Nanobodies

2023-05-15T11:27:38-04:00February 4th, 2022|Articles|

Written by: Yuning Wang, PhD Updated: January 18, 2023 (Published: January 21, 2022) Contents Discovery of Camelid Antibodies What are Camelid Antibodies? Structure of Camelid Antibodies and Nanobodies Advantages of Camelid Antibodies and Nanobodies Camelid Antibodies and Nanobodies for Therapeutic and Research Applications How are Camelid Antibodies [...]

December 2021

Polyclonal Antibody Sequencing in Therapeutics Development Pipelines

2023-06-21T10:58:31-04:00December 20th, 2021|Webinars|

Over the past several years Rapid Novor has been developing the world's best antibody protein sequencing platform, with over 2700 monoclonal antibodies and proteins sequenced. In 2020, they unveiled their most advanced technology to date- REpAb® polyclonal antibody sequencing. The platform combines the world's best protein sequencing technology and NGS to comprehensively mine the antigen specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patient's blood.

Next Generation Protein Sequencing in Veterinary Medicine and Industry

2023-05-15T12:31:25-04:00December 3rd, 2021|Whitepapers|

Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply

October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2023-05-15T12:31:01-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

July 2021

May 2021

Polyclonal Antibody Sequencing with Only Proteomics

2023-06-21T10:56:34-04:00May 13th, 2021|Webinars|

Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®.  After successfully launching their proteogenomics based sequencing technology to deconvolute the immune response, the team has further evolved the technology and has derived the most abundant mAb sequences directly from rabbit blood using only proteomics. The talk will surround the development, progress and use cases for REpAb®.

April 2021

Leveraging pAbs for Therapeutic Development

2023-06-21T10:56:21-04:00April 13th, 2021|Webinars|

Over the past several years Rapid Novor has been developing the world’s best antibody protein sequencing platform, sequencing over 2700 monoclonal antibodies and proteins. In 2020, they unveiled their most advanced technology to date - REpAb® polyclonal antibody sequencing. The platform combines the world’s best protein sequencing technology and NGS to comprehensively mine the antigen-specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patients’ blood.

March 2021

June 2016

Moving Towards Recombinant Monoclonal Antibodies

2023-05-15T11:59:37-04:00June 30th, 2016|Articles|

Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.